RE: Up ?29 Oct 2019 10:07
Who knows but yes a contract or two should make a difference.
This is hardly a sign of confidence though is it?
Oxford, UK - 28 October 2019: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Lorenzo Tallarigo, Chairman of the Group, has purchased 472 ordinary shares of 50p each ("Ordinary Shares") in the Company on 28 October 2019 on the London Stock Exchange at a price of 566.0p per share as set out below under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.
472 shares!!